The U.S. Food and Drug Administration (FDA) has made a significant advancement in treating inherited deafness by approving the first gene therapy targeting genetic mutations in the OTOF gene. This therapy, developed by Regeneron Pharmaceuticals, aims to address the underlying genetic cause of hearing loss rather than relying on traditional assistive devices like hearing aids. Clinical trials revealed that out of 20 children treated, 16 showed improvements in hearing within five months, with some achieving near-normal hearing levels over a longer monitoring period. Parents reported life-changing outcomes for their children. The therapy is delivered through a surgical procedure akin to cochlear implantation and has been deemed safe, with side effects primarily associated with the surgery rather than the therapy itself. Regeneron plans to provide this groundbreaking treatment free of charge to U.S. patients, although families may still incur costs related to the surgical procedure. The company is also exploring regulatory approvals in other countries, though details on costs outside the U.S. remain unclear.